Get the Stockscreener App
2.31
10.81%
-0.28
After Hours:
2.34
0.03
+1.30%
Dogwood Therapeutics Inc stock is traded at $2.31, with a volume of 98,569.
It is down -10.81% in the last 24 hours and down -19.51% over the past month.
Dogwood Therapeutics Inc, formerly Virios Therapeutics Inc, is a development-stage biotechnology company. It is focused on advancing novel antiviral therapies to treat diseases associated with a virus-triggered abnormal immune response, such as fibromyalgia (FM) and long COVID (LC). Its product candidates include IMC-1 and IMC-2. IMC-1 is intended to synergistically suppress herpesvirus activation and replication with a more specific activity against the Epstein-Barr virus (herpesvirus HHV-4, IMC-2 is a combination of valacyclovir and celecoxib.
See More
Previous Close:
$2.59
Open:
$2.6
24h Volume:
98,569
Relative Volume:
1.66
Market Cap:
$77.16M
Revenue:
-
Net Income/Loss:
$-34.26M
P/E Ratio:
-0.1222
EPS:
-18.9056
Net Cash Flow:
$-15.62M
1W Performance:
-22.22%
1M Performance:
-19.51%
6M Performance:
-54.79%
1Y Performance:
-61.82%
1-Day Range:
$2.258
$2.6998
1-Week Range:
$2.258
$3.10
52-Week Range:
$2.258
$9.50
Dogwood Therapeutics Inc Stock (DWTX) Company Profile
Name
Dogwood Therapeutics Inc
Sector
Industry
Phone
(866) 620-8655
Address
44 MILTON AVENUE, ALPHARETTA
Compare DWTX vs VRTX, REGN, ALNY, ARGX, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DWTX
Dogwood Therapeutics Inc
|
2.31 | 86.51M | 0 | -34.26M | -15.62M | -18.91 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Dogwood Therapeutics Inc Stock (DWTX) Latest News
DWTX: 143 Patients Enrolled in Phase 2b Trial of Halneuron Results Expected in 3Q26 - Research Tree
DWTX: 143 Patients Enrolled in Phase 2b Trial of Halneuron®; Results Expected in 3Q26 - Yahoo Finance
US Market Recap: What is the long term forecast for Dogwood Therapeutics Inc stockWeekly Profit Recap & Free Fast Entry Momentum Trade Alerts - baoquankhu1.vn
Dogwood Therapeutics (DWTX) to Release Quarterly Earnings on Monday - Defense World
HC Wainwright Issues Positive Forecast for DWTX Earnings - MarketBeat
If You Invested $1,000 in Dogwood Therapeutics (DWTX) - Stock Titan
History Review: Will Dogwood Therapeutics Inc benefit from government policyTrade Performance Summary & Low Risk High Win Rate Picks - baoquankhu1.vn
Aug Decliners: Will Dogwood Therapeutics Inc benefit from government policyPortfolio Profit Report & Daily Chart Pattern Signals - baoquankhu1.vn
What is HC Wainwright’s Estimate for DWTX FY2030 Earnings? - Defense World
What is HC Wainwright's Estimate for DWTX FY2030 Earnings? - MarketBeat
Performance Recap: Is Dogwood Therapeutics Inc stock showing strong momentum - baoquankhu1.vn
Dogwood Therapeutics 2025 Annual Report – Pipeline, Clinical Progress, Intellectual Property, and Risks in Neuropathic Pain Drug Development - Minichart
Dogwood Therapeutics (DWTX) Q4 Loss Narrows to $0.26, Beats Estimates - AlphaStreet
Moving Averages: Is Dogwood Therapeutics Inc stock showing strong momentum2026 Short Interest & Risk Adjusted Buy and Sell Alerts - baoquankhu1.vn
Dogwood Therapeutics (DWTX) details Halneuron pain program and going-concern risk - Stock Titan
Dogwood Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results - Bitget
DWTX: Halneuron® Phase 2b trial advances, with funding secured through key 2026 milestones - TradingView
Dogwood Therapeutics (Nasdaq: DWTX) ramps R&D and extends cash runway - Stock Titan
Dogwood Therapeutics Q4 net loss narrows on lower expenses - TradingView
Dogwood Therapeutics extends cash runway as pain drug trial advances - Stock Titan
Short Interest in Dogwood Therapeutics, Inc (NASDAQ:DWTX) Decreases By 15.1% - MarketBeat
Dogwood Therapeutics (NASDAQ:DWTX) Shares Up 1.7%Time to Buy? - MarketBeat
Dogwood Therapeutics Shareholders Approve Warrant Exercise Proposal - The Globe and Mail
Dogwood Therapeutics, Inc. 8-K SEC Filing March 11, 2026: Company Information, Stock, and Key Details - Minichart
Dogwood Therapeutics (Nasdaq: DWTX) holders back major warrant exercise - Stock Titan
CK Life Sciences Establishes Sequencio Therapeutics to Advance Therapeutic Cancer Vaccines Development - The Manila Times
Sentiment Watch: What is the long term forecast for Dogwood Therapeutics Inc stockTrend Reversal & Accurate Buy Signal Alerts - baoquankhu1.vn
Maxim Group Sticks to Its Buy Rating for Dogwood Therapeutics (DWTX) - The Globe and Mail
Dogwood Therapeutics (DWTX) CMO receives grant of 82,500 stock options - Stock Titan
DWTX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Bull Run: Does Dogwood Therapeutics Inc stock benefit from AI growthJuly 2025 Gainers & Reliable Entry Point Trade Alerts - baoquankhu1.vn
Shorts Report: Is Dogwood Therapeutics Inc stock showing strong momentumDollar Strength & Real-Time Stock Movement Alerts - baoquankhu1.vn
Aug Update: Does Dogwood Therapeutics Inc stock benefit from AI growthWeekly Stock Summary & Reliable Breakout Forecasts - baoquankhu1.vn
DWTXDogwood Therapeutics Latest Stock News & Market Updates - Stock Titan
Dogwood Therapeutics (NASDAQ:DWTX) Earns Buy Rating from HC Wainwright - Defense World
Analysts Offer Insights on Healthcare Companies: Corcept Therapeutics (CORT), Praxis Precision Medicines (PRAX) and Dogwood Therapeutics (DWTX) - The Globe and Mail
Is Dogwood Therapeutics Inc. stock showing strong momentumMarket Volume Report & Growth Oriented Trading Recommendations - mfd.ru
What’s the MACD signal for Dogwood Therapeutics Inc.Trade Entry Summary & Reliable Entry Point Trade Alerts - mfd.ru
Market Wrap: How cyclical is Dogwood Therapeutics Incs revenue streamDividend Hike & Free Safe Capital Growth Stock Tips - baoquankhu1.vn
Pullback Watch: Whats the MACD signal for Dogwood Therapeutics Inc2025 Key Highlights & Expert Approved Momentum Ideas - baoquankhu1.vn
What’s the analyst consensus on Dogwood Therapeutics Inc.July 2025 Gainers & Reliable Price Action Trade Plans - mfd.ru
Will Dogwood Therapeutics Inc. stock benefit from AI adoption2025 Winners & Losers & Weekly Top Performers Watchlists - mfd.ru
Will Dogwood Therapeutics Inc. benefit from geopolitical trendsEarnings Recap Report & Risk Managed Investment Strategies - mfd.ru
Warrant approval could dilute Dogwood Therapeutics (NASDAQ: DWTX) holders - Stock Titan
How is Dogwood Therapeutics Inc. managing supply chain issuesQuarterly Portfolio Review & Low Risk Entry Point Guides - mfd.ru
What is the PEG ratio of Dogwood Therapeutics Inc.Weekly Profit Analysis & Accurate Buy Signal Notifications - mfd.ru
Why Dogwood Therapeutics Inc. stock could benefit from AI revolutionJuly 2025 Snapshot & Technical Confirmation Trade Alerts - mfd.ru
DWTX: Financing Secures Funding Through Phase 2b Data Readout - Smartkarma
Institution Moves: Will Dogwood Therapeutics Inc. benefit from geopolitical trends2025 Macro Impact & Precise Swing Trade Entry Alerts - baoquankhu1.vn
Dogwood Therapeutics Announces 50% Enrollment in Ongoing Halneuron® Phase 2b Trial, Top Line Results Anticipated in Q3 2026 - markets.businessinsider.com
Cancer pain drug Halneuron shows early promise as major trial hits halfway - Stock Titan
Dogwood Therapeutics Inc Stock (DWTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.82%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):